BridgeBio Pharma, Inc. Capital Expenditures Incurred but Not yet Paid
BridgeBio Pharma, Inc. (BBIO) reported Capital Expenditures Incurred but Not yet Paid of $12.00 thousand for the 3-month period ending 2026-03-31, per its 10-Q filed 2026-05-07.
Financial Statements › Cash Flow › Other Cash Flow Items
us-gaap:CapitalExpendituresIncurredButNotYetPaid · last filed 2026-05-07
- BridgeBio Pharma, Inc. capital expenditures incurred but not yet paid for the quarter ending 2026-03-31 was $12.00K, a 96.44% decline year-over-year.
- BridgeBio Pharma, Inc. capital expenditures incurred but not yet paid for the quarter ending 2025-12-31 was $31.00K, a 520.00% increase year-over-year.
- BridgeBio Pharma, Inc. capital expenditures incurred but not yet paid for the quarter ending 2025-09-30 was $12.00K, a 94.12% decline year-over-year.
- BridgeBio Pharma, Inc. capital expenditures incurred but not yet paid for the quarter ending 2025-06-30 was -$337.00K.
- BridgeBio Pharma, Inc. capital expenditures incurred but not yet paid for fiscal 2025 was $43.00K, a 84.59% decline from fiscal 2024.
- BridgeBio Pharma, Inc. capital expenditures incurred but not yet paid for fiscal 2024 was $279.00K, a 179.00% increase from fiscal 2023.
- BridgeBio Pharma, Inc. capital expenditures incurred but not yet paid for fiscal 2023 was $100.00K, a 112.77% increase from fiscal 2022.
- BridgeBio Pharma, Inc. capital expenditures incurred but not yet paid for fiscal 2022 was $47.00K, a 91.65% decline from fiscal 2021.
| Period end | Capital Expenditures Incurred but Not yet Paid 3 month | Capital Expenditures Incurred but Not yet Paid 6 month | Capital Expenditures Incurred but Not yet Paid 9 month | Capital Expenditures Incurred but Not yet Paid 12 month |
|---|---|---|---|---|
| 2026-03-31 | $12.00K 10-Q · filed 2026-05-07 | $43.00K derived: sum of 2 quarters · filed 2026-05-07 | $55.00K derived: sum of 3 quarters · filed 2026-05-07 | -$282.00K derived: sum of 4 quarters · filed 2026-05-07 |
| 2025-12-31 | $31.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $43.00K derived: sum of 2 quarters · filed 2026-02-24 | -$294.00K derived: sum of 3 quarters · filed 2026-02-24 | $43.00K 10-K · filed 2026-02-24 |
| 2025-09-30 | $12.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-29 | -$325.00K derived: sum of 2 quarters · filed 2025-10-29 | $12.00K 10-Q · filed 2025-10-29 | $17.00K derived: sum of 4 quarters · filed 2026-05-07 |
| 2025-06-30 | -$337.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | $0.00 10-Q · filed 2025-08-05 | $5.00K derived: sum of 3 quarters · filed 2026-05-07 | $209.00K derived: sum of 4 quarters · filed 2026-05-07 |
| 2025-03-31 | $337.00K 10-Q · filed 2026-05-07 | $342.00K derived: sum of 2 quarters · filed 2026-05-07 | $546.00K derived: sum of 3 quarters · filed 2026-05-07 | $546.00K derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $5.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $209.00K derived: sum of 2 quarters · filed 2026-02-24 | $209.00K derived: sum of 3 quarters · filed 2026-02-24 | $279.00K 10-K · filed 2026-02-24 |
| 2024-09-30 | $204.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-29 | $204.00K derived: sum of 2 quarters · filed 2025-10-29 | $274.00K 10-Q · filed 2025-10-29 | $182.00K derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | $70.00K 10-Q · filed 2025-08-05 | -$22.00K derived: sum of 3 quarters · filed 2026-02-24 | $39.00K derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-03-31 | $70.00K 10-Q · filed 2025-04-29 | -$22.00K derived: sum of 2 quarters · filed 2026-02-24 | $39.00K derived: sum of 3 quarters · filed 2026-02-24 | $74.00K derived: sum of 4 quarters · filed 2026-02-24 |
| 2023-12-31 | -$92.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | -$31.00K derived: sum of 2 quarters · filed 2026-02-24 | $4.00K derived: sum of 3 quarters · filed 2026-02-24 | $100.00K 10-K · filed 2026-02-24 |
| 2023-09-30 | $61.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $96.00K derived: sum of 2 quarters · filed 2024-11-12 | $192.00K 10-Q · filed 2024-11-12 | $179.00K derived: sum of 4 quarters · filed 2025-02-20 |
| 2023-06-30 | $35.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-01 | $131.00K 10-Q · filed 2024-08-01 | $118.00K derived: sum of 3 quarters · filed 2025-02-20 | $105.00K derived: sum of 4 quarters · filed 2025-02-20 |
| 2023-03-31 | $96.00K 10-Q · filed 2024-05-02 | $83.00K derived: sum of 2 quarters · filed 2025-02-20 | $70.00K derived: sum of 3 quarters · filed 2025-02-20 | -$607.00K derived: sum of 4 quarters · filed 2025-02-20 |
| 2022-12-31 | -$13.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-20 | -$26.00K derived: sum of 2 quarters · filed 2025-02-20 | -$703.00K derived: sum of 3 quarters · filed 2025-02-20 | $47.00K 10-K · filed 2025-02-20 |
| 2022-09-30 | -$13.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | -$690.00K derived: sum of 2 quarters · filed 2023-11-02 | $60.00K 10-Q · filed 2023-11-02 | |
| 2022-06-30 | -$677.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | $73.00K 10-Q · filed 2023-08-03 | ||
| 2022-03-31 | $750.00K 10-Q · filed 2023-05-04 | |||
| 2021-12-31 | $563.00K 10-K · filed 2024-02-22 | |||
| 2021-06-30 | -$464.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $1.32M 10-Q · filed 2022-08-04 | ||
| 2021-03-31 | $1.79M 10-Q · filed 2022-05-05 | |||
| 2020-12-31 | $1.10M 10-K · filed 2023-02-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |